Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-03-08 |
Tizona Therapeutics (USA - CA) |
$43 Million |
series B financing round |
Abingworth (UK) Canaan Partners (USA - CA - Israel) Lightstone Ventures (USA - CA) MPM Capital (USA - MA) Amgen Ventures (USA - CA) Astellas Venture Management (USA - CA) InterWest Partners InterWest Partners |
Autoimmune diseases - Cancer - Oncology |
Series B financing round |
2016-03-07 |
Argos Therapeutics (USA - NC) |
up to $60 million |
private placement |
|
|
Private placement |
2016-03-07 |
Cempra (USA - NC) |
$25.5 million |
grant |
Department of Health and Human Services (USA) |
Infectious diseases |
Grant |
2016-03-03 |
Autolus (UK) |
£40 million |
series B financing round |
Woodford Investment Management (UK) Perceptive Bioscience Investments (UK) |
Cancer - Oncology |
Series B financing round |
2016-02-29 |
ARqule (USA -MA) |
$15.2 Million |
private placement |
institutional and accredited investors |
Cancer - Oncology |
Private placement |
2016-02-26 |
Diamyd Medical (Sweden) |
SEK 22.1 million (€ 2.4 million) |
private placement |
Bertil Lindkvist, Anders Essen-Möller |
Autoimmune diseases - Metabolic diseases |
Private placement |
2016-02-25 |
Cobra Biologics (Sweden) The Centre for Process Innovation (UK) |
£1.4 million |
grant |
Innovate UK (UK) |
Technology - Services |
Grant |
2016-02-23 |
Oxford Biomedica (UK) |
|
private placement |
|
|
Private placement |
2016-02-16 |
Apogenix (Germany) |
€3 Million |
grant |
German Federal Ministry of Education and Research (BMBF) (Germany) |
Cancer - Oncology |
Grant |
2016-02-09 |
Westmead Institute’s Centre for Infectious Diseases and Microbiology (Australia) Ampliphi Biosciences (USA - VA) |
AUD $860,000 (€ 544 000 - $ 608 000) |
grant |
Australian Government (Australia) |
Infectious diseases |
Grant |
2016-02-05 |
Tivorsan Pharmaceuticals (USA - RI) |
$1.8 million |
financing round |
|
Rare diseases - Genetic diseases - Neuromuscular diseases |
Financing round |
2016-02-02 |
Confo Therapeutics (Belgium) |
fundraising |
€6.7 million |
Capricorn Venture Partners (Belgium) Qbic (Belgium) SOFI (Belgium) MINTS (University of Michigan) (USA - MI) Participatie Maatschappij Vlaanderen NV (PMV) (Belgium) V-Bio Ventures (V-Bio) (Belgium) VIB (Belgium) |
|
Fundraising |
2016-02-01 |
Bionor Pharma (Norway) |
NOK 9.2 million (€ 0.97 million) |
grant |
the Research Council of Norway (Norway) |
Infectious diseases |
Grant |
2016-02-01 |
Modulate Therapeutics (Canada) |
|
|
TVM Life Science VII (Canada) Eli Lilly (USA - IN) |
Cancer - Oncology |
Financing round |
2016-01-28 |
Transgene (France) |
€ 20 million |
loan |
European Investment Bank (EIB) |
Infectious diseases |
Loan |
2016-01-27 |
Adicet Bio (USA - CA) |
$51 million |
series A financing round |
OrbiMed (USA - NY) Pontifax (Israel) Novartis Venture Fund (Switzerland) |
Cancer - Oncology - Immunological diseases |
Series A financing round |
2016-01-20 |
Mucosis (The Netherlands) |
€3.7 milion + € 2 million |
grant and fundraising |
The Wellcome Trust (UK) |
Infectious diseases |
Grant |
2016-01-19 |
Inovio Pharmaceuticals (USA - PA) |
$500,000 |
grant |
U.S. Army’s Small Business Innovation Research (SBIR) program |
Technology - Services - Infectious diseases |
Grant |
2016-01-14 |
icometrix (Belgium) |
€ 2 million |
financing round |
Capricorn ICT Arkiv (Belgium) Annie Vereecken (Biover II) (Belgium) former Cartagenia (now part of Agilent Technologies) CEO Herman Verrels (Belgium) University of Antwerp (Belgium) University of Leuven (Belgium) Antwerp University Hospital (Belgium) |
Technology - Services |
Financing round |
2016-01-13 |
Tiziana Life Sciences (UK) |
£709,406 (US$1,021,523 - €944883) |
private placement |
|
Autoimmune diseases - Cancer - Oncology |
Private placement |